Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...

Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating ...

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...

The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...